23 Jul, 2026
According to Straits Research, the global neurology clinical trials market size was valued at $6.25 billion in 2025 and is projected to grow from $6.6 billion in 2026 to $10.26 billion by 2034, registering a CAGR of 5.67% during the forecast period 2026–2034.
Neuroscience continues to attract a decent amount of venture capital. It received USD 1.5 billion in venture capital funding, the second-highest sum after cancer, indicating that investors expect a massive pharmaceutical acquisition to pay off soon. Early disease identification stimulates investment and deal-making in the complicated neuroscience industry, especially for pain and Alzheimer's. This occurs as the industry attempts to move past the numerous late-stage trial failures of recent years. No other treatment field matches the volume of agreements in cancer, but neurology is among the closest competitors. There has been average but steady growth in the number of licensing sales relating to neuroscience over the past decade, despite a decrease in the total projected value. In 80–90% of neuroscience agreements, the primary focus is neurological, reflecting the intensity of research and development activities in both sectors.
The utilization of novel outcomes, more patient participation, and a reduction in the burden placed on patients are all potential elements that could improve the efficiency and efficacy of neurology clinical trials. These potential benefits could be realized through the application of technological advancements. Using cutting-edge technology, such as virtual clinical trials, remote monitoring, and wearable devices to conduct clinical trials in a manner that is more responsive to the requirements of participants is one way to achieve the goal of making clinical trials more patient-centered.
This is mainly related to increased neurological ailments such as dementia, stroke, peripheral neuropathy, and spending on neurological research and development. Numerous prestigious pharmaceutical firms have made neuroscience one of their crucial research foci. Alzheimer's medicines created by AstraZeneca, Lilly, Merck, Novartis, Pfizer, and Roche failed in late-stage testing. However, Biogen, a prominent neuroscience business, wants to persuade authorities to authorize a medicine that acts similarly to the unsuccessful attempts of its competitors. After achieving substantial advances against Alzheimer's disease, pharmaceutical companies are now focusing their efforts on other neurological disorders, such as spinal muscular atrophy. The authorization has been given for Biogen and Novartis's effective treatments.
Several factors contribute to the demand for neurology clinical trial solutions accessible on the global market. This includes the growing prevalence of neurological disorders such as dementia, peripheral neuropathy, and stroke and the increased fiscal spending to advance neurological research efforts. The rise of the neurology clinical trials market results from the rising incidence of numerous genetic and neurological disorders. This expert assessment is a comprehensive review of the micro and macroeconomic factors anticipated to influence the dynamics of the neurology clinical trials market between 2020 and 2030. The research report provides information on specific submarkets comprising the global market for neurology clinical trials.
Neurology clinical trials could be more effective and productive if they employ unique outcomes, enhanced patient engagement, and reduced patient burden. These advantages could be realized by employing technological breakthroughs. The goal of making clinical trials more patient-centered can be reached using innovative technologies such as remote monitoring, virtual clinical trials, and wearable gadgets. Contributing to this advancement are technological advances and discoveries, the incorporation of brand-new and cutting-edge technologies like remote monitoring, virtual clinical trials, and wearable devices, and increasing investments from the public and private sectors. In the following years, there is also expected to be an increase in the prevalence of Huntington's disease, which is likely to create market prospects for neurology clinical trials worldwide.
The market for neurology clinical trials was dominated by North America in 2021, with the region accounting for 45.8 % of the total revenue. The rising prevalence of neurological conditions in the area and the large number of businesses already engaged in clinical research have combined to create a pressing demand for clinical research in the field of neurology. Alzheimer's disease and different types of dementia are expected to affect an estimated 8.4 million individuals in the U.S. who are more aged by 2030. This number is expected to rise in tandem with the aging of the population and the improvement in life expectancy.
During the period in question, it is expected that the market for neurology clinical trials in the Middle East and Africa will develop at a compound annual growth rate of 8.2 percent. Despite increasing conditions associated with growing longevity, such as stroke, the Sub-Saharan Africa region is beset by neurological, psychiatric, developmental, and drug use disorders caused or exacerbated by a lack of proper nutrition and infectious disease. These disorders include drug use. Both major depression and post-traumatic stress disorder are becoming increasingly prevalent problems throughout the Middle East and North Africa due to the region's protracted state of war.
sales@straitsresearch.com